◆ TICKERBASE · US STOCK FINANCIAL DATA LIBRARY

HomeAll stocks › XENE

Xenon Pharmaceuticals Inc. (XENE) Financial History

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Biotechnology · DATA UPDATED 2026-07-10

Xenon Pharmaceuticals Inc. (XENE) operates in the Biotechnology industry and is headquartered in Burnaby, Canada with about 358 employees. Its market capitalization is roughly $7 billion. In the fiscal year ended 2025-12-31, XENE reported $8M in revenue and ($346M) in net income.

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders.

Interactive charts & full statements →

XENE Revenue & Earnings History — Annual Income Statement

Income statement2025-12-312024-12-312023-12-312022-12-312021-12-31
Total Revenue$8M$0M$0M$9M
Operating Income (EBIT)($373M)($279M)($214M)($129M)
Net Income($346M)($234M)($182M)($125M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

XENE Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement2026-03-312025-12-312025-09-302025-06-302025-03-31
Total Revenue$0M$0M$0M$0M$8M
Operating Income (EBIT)($112M)($110M)($96M)($94M)($73M)
Net Income($102M)($105M)($91M)($85M)($65M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

XENE Free Cash Flow History

XENE Balance Sheet History

Balance sheet2025-12-312024-12-312023-12-312022-12-312021-12-31
Total Assets$633M$798M$965M$754M
Total Liabilities$51M$43M$37M$33M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive XENE viewer.

Other Companies in Biotechnology

← XELBAll stocksXERS →

About TickerBase · Data methodology & sources

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.